1 The most frequently reported grade 3 or higher adverse
events were abnormal blood chemistry results (33 [15%] of 221
2 Progression-free survival (PFS), OS, and adverse
events were also assessed.
3 Analyses of skeletal-related
events were also done in the intention-to-treat population.
4 In total, 1426
events were analysed.
5 t sensitivity, endothelial cell count, and possible adverse
events were assessed at least 12 months postoperatively.
6 Early progression-free survival (PFS)
events were associated with low tumor mutational burden/T cel
7 No serious adverse
events were attributed to dihydroartemisinin-piperaquine.
8 The two
events were causally related as suggested by the finding that
9 Clinical
events were collected for 12 months.
10 These early
events were concomitant with deregulation of circulating miRN
11 Plume pharmacology and plume-like neural Ca(2+)
events were consistent with action-potential-independent spon
12 All patients had engraftment, and adverse
events were consistent with effects of the preparative chemot
13 Yet, whether CVD
events were consistently reported in pivotal trials supportin
14 CAD
events were defined by myocardial infarction or CAD mortality
15 Local reactions and systemic
events were dose-dependent, generally mild to moderate, and t
16 Characterising how climatic
events were expressed in local environments is crucial to und
17 The most common drug-related adverse
events were fatigue, nausea, diarrhea, anorexia, vomiting, pe
18 The most common grade 3-4 adverse
events were febrile neutropenia (22 [66%]), bloodstream infec
19 ified fusions were largely private and 4 specific recurring
events were found both in cortex and in single neurons but no
20 The most common grade 3 or 4 adverse
events were hypertension (88 [27%] of 332 patients in the exp
21 Reported systemic and local
events were mild and transient.
22 All treatment-related adverse
events were mild or moderate in severity and similar across t
23 Most adverse
events were mild.
24 Systemic adverse
events were more common after the second vaccination, particu
25 ILD
events were more common among those with early/mild ILA at en
26 Serious adverse
events were more common with systematic treatment.
27 Adverse
events were more common with zoledronic acid than with placeb
28 neurysm coiling or balloon-assisted coiling, thromboembolic
events were more frequent than were intraoperative rupture.
29 Adverse
events were mostly mild and equally distributed (15/23 [65.2%
30 The most common treatment-related grade 3-4 adverse
events were neutropenia (15 [50%] of 30 patients), increased
31 The most common any-cause grade 3 or worse adverse
events were neutropenia (85 [32%] of 266 patients in the durv
32 (54 years, 56% women, 23% black, 44% with FHx), 3,114 ASCVD
events were observed during 21 years of follow-up.
33 - or race-based CAC interactions for ASCVD, CHD, and stroke
events were observed.
34 iations between eGFR, cardiac mechanics, and cardiovascular
events were partly mediated via CFR.
35 The most common grade 3-4 adverse
events were raised gamma-glutamyltransferase (13 [16%] of 80
36 and overall major adverse cardiovascular or cerebrovascular
events were recorded.
37 HC-102 was well tolerated and no study drug-related adverse
events were recorded.
38 Two serious adverse
events were reported - both resolved without sequelae and nei
39 Solicited adverse
events were reported by 44% of vaccine recipients and were tr
40 Adverse
events were reported in 108 (69%) of 156 patients in the abro
41 Adverse
events were reported in 58.4% of patients; most (94.4%) were
42 Serious adverse
events were reported in five (3%) of 156 patients in the abro
43 Of these, 18
events were reported in the active group and 8 in the control
44 Eight serious adverse
events were reported with capsular release and two with manip
45 No severe vaccine-related adverse
events were reported.
46 itoring board halted the trial when the numbers of clinical
events were significantly lower among children receiving esca
47 Cumulative rates of serious adverse
events were similar in TAK-003 (4.0%) and placebo (4.8%) reci
48 Adverse
events were similar in the two trial groups, with no notable
49 most common (>=20% patients in any group) grade 3-4 adverse
events were thrombocytopenia (33 [42%] of 78, 26 [31%] of 83,
50 Serious procedure-related adverse
events were uncommon.